New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
10:07 EDTCAB, ATHL, ARIA, REPH, HOLI, BMRN, AEO, RSPP, CSTM, ATW, ALE, SNSS, NMMOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: ARIAD (ARIA) coverage transitioned with a Neutral at UBS... Allete (ALE) initiated with a Neutral at JPMorgan... American Eagle (AEO) initiated with a Fair Value at CRT Capital... Athlon Energy (ATHL) initiated with a Buy at Mizuho... Atwood Oceanics (ATW) initiated with a Hold at Deutsche Bank... BioMarin (BMRN) coverage transitioned with a Buy at UBS... Cabela's (CAB) initiated with a Neutral at Goldman... Constellium (CSTM) initiated with a Buy at Sterne Agee... Hollysys Automation (HOLI) initiated with a Buy at Goldman... Navios Maritime Partners (NMM) initiated with a Buy at Jefferies... RSP Permian (RSPP) initiated with a Buy at Mizuho... Recro Pharma (REPH) initiated with a Buy at Aegis... Sunesis (SNSS) initiated with a Buy at UBS.
News For ARIA;ALE;AEO;ATHL;ATW;BMRN;CAB;CSTM;HOLI;NMM;RSPP;REPH;SNSS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 24, 2015
07:38 EDTSNSSSunesis downgraded to Sell from Buy at Roth Capital
Roth Capital downgraded Sunesis to Sell from Buy with a $1 price target following the mixed regulatory update for vosaroxin.
07:36 EDTSNSSSunesis downgraded to Market Perform from Outperform at Cowen
Cowen downgraded Sunesis following news that recent FDA discussions were not supportive of an NDA filing for vosaroxin.
07:04 EDTREPHRecro Pharma announces additional information for Dex-IN Phase II clinical trial
Recro Pharma announced additional results from the Phase II clinical trial for Dex-IN, a proprietary intranasal formulation of dexmedetomidine, for the treatment of acute pain in adult patients undergoing bunionectomy surgery. As previously released, Dex-IN met the primary endpoint of the clinical trial in demonstrating significant pain relief compared with placebo over 48 hours. The company plans to meet with the FDA to discuss the company's Phase III plans and determine what, if any, additional information will be required in association with the Phase III clinical program for Dex-IN. The Phase II trial was a randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of Recro Pharma's proprietary intranasal formulation of dexmedetomidine, Dex-IN, in adult patients undergoing bunionectomy surgery, initiating dosing of study medication on Post Op Day 1. Patients who met the eligibility criteria were randomized to either a 50g dose of Dex-IN or a placebo intranasal dose given every 6 hours. Following the beginning of treatment, patients remained under observation for 48 hours at study centers. Patients were followed for 7 days after the initial dose of study medication. There was an oral opioid rescue treatment available to patients in either treatment group, if required, to provide adequate pain relief. A total of 168 patients were randomized and received study medication in the clinical trial, 84 patients in each treatment group. The key subject characteristics are listed in Table 1 below. The one discontinued subject was for a serious adverse event of hypotension.
July 23, 2015
19:06 EDTSNSSOn The Fly: After Hours Movers
UP AFTER EARNINGS: Amazon (AMZN), up 17.2%... Marketo (MKTO), up 15.4%... Juniper Networks (JNPR), up 9.9%... NetGear (NTGR), up 9.2%... Qlik Technologies (QLIK), up 9.1%... LogMeIn (LOGM), up 9.9%... Pandora (P), up 10.3%... Mitek Systems (MITK), up 7.8%... Proofpoint (PFPT), up 5.1%... Supreme Industries (STS), up 4.7%... Skyworks (SWKS), up 3.6%... IGI Laboratories (IG), up 3.7%... Maxim Integrated Products (MXIM), up 4.1%... Boyd Gaming (BYD), up 4.1%... Trinity Industries (TRN), up 5%... Trinity Industries (N), up 3.2%... Starbucks (SBUX), up 4.5%. ALSO HIGHER: Qorvo (QRVO), up 2.7% after Skyworks reported quarterly results. DOWN AFTER EARNINGS: TrueCar (TRUE), down 33.1% after reporting quarterly results and cutting fiscal 2015 revenue guidance... Tripadvisor (TRIP), down 9.2%... Align Technology (ALGN), down 7.4%... Capital One (COF), down 4.9%... PMC-Sierra (PMCS), down 9.1%... athenahealth (ATHN), down 2.1%. ALSO LOWER: Sunesis Pharmaceuticals (SNSS), down 59.7% after giving vosaroxin regulatory update... Avalanche Biotechnologies (AAVL), down 5.6% after CEO Thomas Chalberg, Jr., Ph.D. resigns and Hans Hull name interim CEO.
16:21 EDTSNSSSunesis drops 55% after giving vosaroxin regulatory update
16:20 EDTSNSSSunesis CEO says disappointed with outcome of meeting with FDA
Subscribe for More Information
16:19 EDTSNSSSunesis says FDA did not support filing for vosaroxin in AML at this time
Subscribe for More Information
12:32 EDTCABOn The Fly: Top stock stories at midday
Subscribe for More Information
09:13 EDTCABOn The Fly: Pre-market Movers
Subscribe for More Information
08:10 EDTCABCabela's sees high single to low double digit growth rate in FY15 EPS
Subscribe for More Information
08:10 EDTCABCabela's reports Q2 EPS 56c, consensus 62c
Reports Q2 revenue $836.3M, consensus $852.89M. Retail store revenue increased 13.9% to $570.1 million; Direct revenue decreased 7.0% to $136.8 million; and Financial Services revenue increased 14.2% to $124.9 million. During the period, consolidated comparable store sales decreased 0.9%. Net income was $40.1 million compared to $43.5 million in the year ago quarter, and earnings per diluted share were $0.56 compared to $0.61 in the year ago quarter.
07:43 EDTAEOStephens to hold a tour
Subscribe for More Information
July 22, 2015
15:26 EDTCABNotable companies reporting before tomorrow's open
Subscribe for More Information
July 21, 2015
07:59 EDTBMRNBioMarin gene therapy an overhang for Baxalta, says JPMorgan
Subscribe for More Information
July 20, 2015
14:32 EDTBMRNFDA panel likely to review Sarepta, BioMarin drugs in November, TheStreet says
Subscribe for More Information
11:03 EDTBMRNSarepta rises after Roth says added data can keep it ahead of BioMarin
Subscribe for More Information
08:47 EDTBMRNBioMarin reports Abrazo Phase 2 trial met threshold for tumor reduction
Subscribe for More Information
July 17, 2015
15:03 EDTREPHTourbillon Capital reports 7% passive stake in Recro Pharma
This was reported earlier in a filing.
14:35 EDTREPHRecro Pharma entered into supply pact with Alkermes
Subscribe for More Information
08:02 EDTREPHRecro Pharma Phase II clinical trial of Dex-IN met primary endpoint
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use